BrainsWay Ltd. (BWAY)
| Market Cap | 406.86M +31.0% |
| Revenue (ttm) | 60.70M +31.7% |
| Net Income | 9.44M +76.7% |
| EPS | 0.21 +109.9% |
| Shares Out | 40.13M |
| PE Ratio | 47.60 |
| Forward PE | 28.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 183,573 |
| Open | 10.31 |
| Previous Close | 10.25 |
| Day's Range | 9.71 - 10.31 |
| 52-Week Range | 7.14 - 17.40 |
| Beta | 0.13 |
| Analysts | Strong Buy |
| Price Target | 19.27 (+90.6%) |
| Earnings Date | Nov 10, 2026 |
About BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves ... [Read more]
Financial Performance
In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price target is $19.27, which is an increase of 90.60% from the latest price.
News
BrainsWay: 3 Key Takeaways for Long-Term Investors
Strategic partnerships with enterprise networks could sustain BrainsWay's growth as its installed base expands beyond 2,000 systems.
BrainsWay (BWAY) Q3 2026 Earnings Call Transcript
Shipments and recurring demand both climbed sharply this quarter.
What Brainsway (BWAY) Said on Its Q3 Earnings Call
Brainsway NASDAQ: BWAY reported 34% revenue growth and a more than doubling of operating income in the third quarter of 2026, as shipments of its Deep TMS systems increased and reimbursement coverage ...
Brainsway reports Q3 EPS 5c, consensus 9c
Reports Q3 revenue $18.15M, consensus $17.8M. “Our third-quarter results demonstrate our ability to translate strong revenue growth into higher profitability and cash generation. Revenue increased 34%...
Brainsway backs FY26 revenue view $68M-$70M, consensus $69.16M
The company said, “Based on strong performance and increased visibility into the remainder of the year, BrainsWay (BWAY) now expects full-year 2026 results to be at the upper end of…
BrainsWay Releases Q3 2026 Financial Results
BrainsWay Ltd. The post BrainsWay Releases Q3 2026 Financial Results first appeared on Alphastreet .
BrainsWay Earnings Call Transcript: Q3 2026
Q3 revenue grew 34% and adjusted EBITDA rose 92% YoY, with gross margin at 78% and RPO up 31% to ~$85m. FY26 results are expected at the upper end of guidance, with further margin gains targeted.
BrainsWay Earnings release: Q3 2026
BrainsWay released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
BrainsWay Slides: Investor presentation
BrainsWay has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
Brainsway announces strategic collaboration with Mindful Health Solutions
BrainsWay (BWAY) announced a strategic collaboration with Mindful Health Solutions, an established provider of comprehensive behavioral health and interventional psychiatry services. In August, Mindfu...
BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatm...
BrainsWay Expands U.S. Insurance Coverage for Deep TMS Treatment of OCD to Over 118 Million Lives
BrainsWay Ltd. announced an expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS in the treatment of patients suffering from obsessive compu...
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
BrainsWay - Depositary Receipt Price Target Increased by 218.89% to $0.20
The average one-year price target for BrainsWay - Depositary Receipt (NASDAQGM:BWAY) has been revised to $0.20 / share. This is an increase of 218.89% from the prior estimate of $0.06 dated October 1,...
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments Partnership with Established Southern Cali...
Brainsway reports rise in Swift Accelerated Deep TMS protocol coverage
BrainsWay (BWAY) announced further expansion in the number of medical policies across the U.S. providing coverage for its Swift Accelerated Deep TMS protocol. With this update, there are now over…
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
Brainsway publishes results from pilot study
BrainsWay (BWAY) announced the publication of results from a pilot study evaluating the company’s proprietary Deep Transcranial Magnetic Stimulation technology in patients with co-occurring Major Depr...
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
Brainsway price target raised to $19 from $17 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Brainsway (BWAY) to $19 from $17 and keeps a Buy rating on the shares. The company’s Q2 financial results…
Brainsway reports Q2 EPS 7c, consensus 7c
Reports Q2 revenue $12.77M, consensus $16.54M. “This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in operating leverage. Revenue reached a re...
Brainsway raises FY26 revenue view to $68M-$70M from $66M-$68M
Consensus $67.65M. Narrows FY26 adjusted EBITDA view to $13M-$14M from $12M-$14M. “This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in opera...
Brainsway price target raised to $18.80 from $18 at Ladenburg
Ladenburg raised the firm’s price target on Brainsway (BWAY) to $18.80 from $18 and keeps a Buy rating on the shares post the Q2 report. The firm says the company’s…
Brainsway Q2 Earnings Call Highlights
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its ac...
BrainsWay Earnings Call Transcript: Q2 2026
Q2 2026 saw 35% revenue growth, margin expansion, and strong recurring revenue visibility, driven by robust Deep TMS system demand and SWIFT protocol adoption. Full-year guidance was raised, supported by a growing backlog, strategic investments, and a debt-free balance sheet.